GDF15 research from bench to bedside
- PMID: 39454578
- DOI: 10.1016/j.ccell.2024.10.002
GDF15 research from bench to bedside
Abstract
Pre-clinical data suggest that increased circulating growth differentiation factor 15 (GDF15) is a cause of both anorexia/cachexia syndromes and hyperemesis gravidarum in pregnancy, serious conditions with no highly effective treatment. A phase 2 study of a therapeutic GDF15 monoclonal antibody in the New England Journal of Medicine suggests that effective treatment of anorexia/cachexia in cancer may be approaching.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests S.N.B. and D.A.B. are inventors on patents commercialized by St Vincent’s Hospital, Sydney, relating to the diagnostic and therapeutic use of GDF15, including for cachexia exemplified by patent family derived from PCT/AU2005/000525 (WO 2005/099746).